This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.
Status: Recruiting
Location: See all (43) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Male or female, 18 years of age or older
• Patient with confirmed MS diagnosis
• Patient initiating treatment with ofatumumab for the first time
• Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
• Patient not opposed to participation in this study
• Patient willing and able to complete patient questionnaires
Locations
Other Locations
France
Novartis Investigative Site
RECRUITING
Agen
Novartis Investigative Site
RECRUITING
Altkirch
Novartis Investigative Site
RECRUITING
Amiens
Novartis Investigative Site
RECRUITING
Angers
Novartis Investigative Site
RECRUITING
Béthune
Novartis Investigative Site
RECRUITING
Bordeaux
Novartis Investigative Site
RECRUITING
Brest
Novartis Investigative Site
RECRUITING
Cahors
Novartis Investigative Site
RECRUITING
Chambéry
Novartis Investigative Site
RECRUITING
Compiègne
Novartis Investigative Site
RECRUITING
Contamine-sur-arve
Novartis Investigative Site
RECRUITING
Dax
Novartis Investigative Site
RECRUITING
La Rochelle
Novartis Investigative Site
RECRUITING
La Seyne-sur-mer
Novartis Investigative Site
RECRUITING
Le Bouscat
Novartis Investigative Site
RECRUITING
Le Coudray
Novartis Investigative Site
RECRUITING
Lens
Novartis Investigative Site
RECRUITING
Libourne
Novartis Investigative Site
RECRUITING
Lille
Novartis Investigative Site
RECRUITING
Lyon
Novartis Investigative Site
RECRUITING
Mantes-la-jolie
Novartis Investigative Site
RECRUITING
Marseille 01
Novartis Investigative Site
RECRUITING
Mont-de-marsan
Novartis Investigative Site
RECRUITING
Montluçon
Novartis Investigative Site
RECRUITING
Montpellier
Novartis Investigative Site
RECRUITING
Mulhouse
Novartis Investigative Site
RECRUITING
Nîmes
Novartis Investigative Site
RECRUITING
Orsay
Novartis Investigative Site
RECRUITING
Paris
Novartis Investigative Site
RECRUITING
Paris
Novartis Investigative Site
RECRUITING
Pointe À Pitre
Novartis Investigative Site
RECRUITING
Poissy
Novartis Investigative Site
RECRUITING
Pringy
Novartis Investigative Site
RECRUITING
Reims
Novartis Investigative Site
RECRUITING
Rennes
Novartis Investigative Site
RECRUITING
Saint-maur-des-fossés
Novartis Investigative Site
RECRUITING
Saverne
Novartis Investigative Site
RECRUITING
Sélestat
Novartis Investigative Site
RECRUITING
Strasbourg
Novartis Investigative Site
RECRUITING
Toulouse
Novartis Investigative Site
RECRUITING
Tours
Novartis Investigative Site
RECRUITING
Valence
Novartis Investigative Site
RECRUITING
Villeurbanne
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2023-12-21
Estimated Completion Date: 2026-07-31
Participants
Target number of participants: 294
Treatments
ofatumumab
MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals